XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events and Impact of COVID-19 Pandemic
9 Months Ended
Sep. 30, 2020
Subsequent Events and Impact of COVID-19 Pandemic  
Subsequent Events and Impact of COVID-19 Pandemic

(14) Subsequent Events and Impact of COVID-19 Pandemic

In March 2020, the clinical trial sites participating in the Company's Phase 2a trial in AD patients in collaboration with the Alzheimer's Disease Cooperative Study temporarily suspended enrollment of new patients because of the ongoing COVID-19 pandemic. Prior to suspension of enrollment, 14 patients had been enrolled and completed treatment, out of a total trial size of 24 patients. Most of the trial sites have reopened and treatment has begun in the 15th patient. In addition, not all the sites which are expected to participate in the Company’s Phase 2a clinical trial in AD and PD have opened for recruitment and treatment of patients due to restrictions related to COVID-19. Although the Company currently believes its clinical trials will be completed on time, the extent to which the COVID-19 pandemic could have a material impact on the clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain.